The use of PI3K/AKT/mTOR pathway inhibitors plus ET is associated with diarrhea, rash, and hyperglycemia, resulting in discontinuations due to AEs in up to 24% of patients (64, 66, 69). Here, PIK3CA is linked to Hyperglycemia.